Company: SMNR
Filing Date: 2025-10-21
Form Type: S-1
Source: 0001193125-25-245178
Chunk: 259

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-10-21
Form: S-1
Chunk 259
---
ley Act and reduced disclosure obligations regarding executive compensation.

Additionally, we are currently a “smaller reporting company” as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements.

<div align='center'>167</div>

#### Website
Our website address is www.semnurpharma.com. We do not incorporate the information on, or accessible through, our website into this prospectus, and you should not consider any information on, or accessible through, our website as part of prospectus. We have included our website address in this prospectus solely as an inactive textual reference.

<div align='center'>168</div>

EXECUTIVE AND DIRECTOR COMPENSATION Executive Compensation Denali’s Executive Officers and Director Compensation Prior to Completion of the Business Combination None of Denali’s officers or directors have received any compensation for services rendered to Denali. The Sponsor, officers, directors and their respective affiliates will be reimbursed for any out-of-pocket expenses incurred in connection with activities on Denali’s behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Legacy Semnur and Current Executive Compensation To achieve our goals, we have designed, and intend to modify as necessary, our compensation and benefits programs to attract, retain, incentivize and reward deeply talented and qualified executives who share our philosophy and desire to work towards achieving our goals. We believe our compensation programs should promote the success of the Company and align executive incentives with the long-term interests of our stockholders. This section provides an overview of the material components of our executive compensation programs, including a narrative description of the material factors necessary to understand the information disclosed in the summary compensation table below. The following is a discussion and analysis of the material components of the compensation arrangements of Legacy Semnur’s named executive officer for the fiscal year ended December 31, 2024 who became an executive of ours. As an “emerging growth company” as defined in the JOBS Act, we are not required to include a Compensation Discussion and Analysis section and have elected to comply with the scaled disclosure requirements applicable to emerging growth companies. Summary Compensation Table

| Name and Principal Position |     | Year |      |     | Salary ($) |         |     | Bonus($) |   |     | Option     
 Awards ($) |   |     | All Other        
 Compensation ($) |        |    |     | Total ($) |         |
| Jais